scholarly journals Local anesthesia with epinephrine is safe and effective for oral surgery in patients with type 2 diabetes mellitus and coronary disease: a prospective randomized study

Clinics ◽  
2015 ◽  
Vol 70 (3) ◽  
pp. 185-189 ◽  
Author(s):  
MA Santos-Paul ◽  
IL Neves ◽  
RS Neves ◽  
JA Ramires
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Coronary Disease ◽  
Local Anesthesia ◽  
Oral Surgery ◽  
Randomized Study ◽  
Prospective Randomized Study

scholarly journals Impact of pharmacotherapeutic education on medication adherence and adverse outcomes in patients with type 2 diabetes mellitus: a prospective, randomized study

2018 ◽  
Vol 59 (6) ◽  
pp. 290-297 ◽  
Author(s):  
Srećko Marušić ◽  
Petra Meliš ◽  
Marko Lucijanić ◽  
Ivica Grgurević ◽  
Petra Turčić ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Medication Adherence ◽  
Randomized Study ◽  
Adverse Outcomes ◽  
Prospective Randomized Study

scholarly journals Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Wendela Lucia de Ranitz-Greven ◽  
Joline Wilhelma Johanna Beulens ◽  
Lette Birgit Elisabeth Anne Hoeks ◽  
Gerdien Belle-van Meerkerk ◽  
Douwe Hedde Biesma ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Randomized Study ◽  
Insulin Regimen ◽  
Once Daily ◽  
Daily Insulin ◽  
Oral Agents

scholarly journals Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

2017 ◽  
Vol 9 (1) ◽  
pp. 49-66 ◽  
Author(s):  
George Grunberger ◽  
Sarah Camp ◽  
Jeremy Johnson ◽  
Susan Huyck ◽  
Steven G. Terra ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Type 2 Diabetes Mellitus ◽  
Kidney Disease ◽  
Randomized Study

Multicentre, Double-blind, Randomized Study of Mitiglinide Compared with Nateglinide in Type 2 Diabetes Mellitus Patients in China

2009 ◽  
Vol 37 (3) ◽  
pp. 812-821 ◽  
Author(s):  
X Gao ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Glucose Control ◽  
Randomized Study ◽  
Blood Glucose Control ◽  
The Elderly ◽  
Double Blind

This study investigated the non-inferiority of mitiglinide 10–20 mg versus nateglinide 120 mg, given orally three times daily for 20 weeks, in 291 Chinese type 2 diabetes mellitus (DM) patients in whom adequate blood glucose control had not been achieved by diet and exercise. Mitiglinide was started at 10 mg three times daily for 12 weeks and thereafter could be increased to 20 mg three times daily, depending on symptoms. In the mitiglinide and nateglinide groups the change in glycosylated haemoglobin (HbA1c) from baseline to week 12 was −0.53 ± 1.08% and −0.58 ± 1.04%, respectively, and further decreased by −0.77 ± 1.06% and −0.71 ± 1.12%, respectively, at week 20 compared with baseline. The intergroup difference (95% confidence interval) of HbA1c was 0.05% (−0.19, 0.30) at week 12 and 0.06% (−0.31, 0.19) at week 20. Similar changes in HbA1c were seen in patients whose baseline value was < 8.0% as well as in those aged ≥ 60 years. Comparable reductions in other blood glucose variables were noted in the two groups. Adverse events in the mitiglinide and nateglinide groups were noted in 54.5% and 57.9% of patients, respectively. In conclusion, mitiglinide 10–20 mg three times daily provided similar blood glucose control to nateglinide 120 mg three times daily in type 2 DM patients, including the elderly and patients with mild diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document